AIMS: Sufficient myocardial recovery with the subsequent explantation of a left ventricular assist device (LVAD) occurs in approximately 1-2% of the cases. However, follow-up data about this condition are scarcely available in the literature. This study aimed to report the long-term outcomes and clinical management following LVAD explantation. METHODS AND RESULTS: An analysis of the European Registry for Patients with Mechanical Circulatory Support was performed to identify all adult patients with myocardial recovery and successful explantation. Pre-implant characteristics were retrieved and compared with the non-recovery patients. The follow-up data after explantation were collected via a questionnaire. A Kaplan-Meier analysis for freedom of the composite endpoint of death, heart transplantation, LVAD reimplantion, or heart failure (HF) relapse was conducted. A total of 45 (1.4%) cases with myocardial recovery resulting in successful LVAD explantation were identified. Compared with those who did not experience myocardial recovery, the explanted patients were younger (44 vs. 56 years, P < 0.001), had a shorter duration of cardiac disease (P < 0.001), and were less likely to have ischaemic cardiomyopathy (9% vs. 41.8%, P < 0.001). Follow-up after explantation could be acquired in 28 (62%) cases. The median age at LVAD implantation was 43 years (inter-quartile range: 29-52), and 23 (82%) were male. Baseline left ventricular ejection fraction was 18% (inter-quartile range: 10-20%), and 60.7% of the patients had Interagency Registry for Mechanically Assisted Circulatory Support Profile 1 or 2. Aetiologies of HF were dilated cardiomyopathy in 36%, myocarditis in 32%, and ischaemic in 14% of the patients, and 18% had miscellaneous aetiologies. The devices implanted were HeartMate II in 14 (50%), HVAD in 11 (39%), HeartMate 3 in 2 (7%), and 1 unknown with a median duration of support of 410 days (range: 59-1286). The median follow-up after explantation was 26 months (range 0.3-73 months), and 82% of the patients were in New York Heart Association Class I or II. Beta-blockers were prescribed to 85%, angiotensin-converting enzyme inhibitors to 71%, and loop diuretics to 50% of the patients, respectively. Freedom from the composite endpoint was 100% after 30 days and 88% after 2 years. CONCLUSIONS: The survival after LVAD explantation is excellent without the need for heart transplantation or LVAD reimplantation. Only a minority of the patients suffer from a relapse of significant HF.

Clinic for Thoracic and Cardiovascular Surgery Heart and Diabetes Centre NRW Ruhr University Bochum Bad Oeynhausen Germany

Department of Cardiac Surgery University Hospitals Leuven Leuven Belgium

Department of Cardiothoracic and Vascular Surgery German Heart Centre Berlin Berlin Germany

Department of Cardiovascular Surgery Ege Üniversitesi Tıp Fakültesi Izmir Turkey

Department of Cardiovascular Surgery Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Cardiovascular Surgery Universitäts Herzzentrum Freiburg Bad Krozingen Freiburg Germany

DZHK partner site Berlin Berlin Germany

EUROMACS EACTS Windsor UK

Thoraxcenter Department of Cardiology Erasmus University Medical Center Rotterdam The Netherlands

Thoraxcenter Department of Cardiothoracic Surgery Erasmus University Medical Center Rotterdam The Netherlands

Zobrazit více v PubMed

Kirklin JK, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Myers SL, Miller MA, Baldwin JT, Young JB, Naftel DC. Eighth annual INTERMACS report: special focus on framing the impact of adverse events. The Journal of Heart and Lung Transplantation 2017; 36: 1080–1086. PubMed

de By T, Mohacsi P, Gahl B, Zittermann A, Krabatsch T, Gustafsson F, Leprince P, Meyns B, Netuka I, Caliskan K, Castedo E, Musumeci F, Vincentelli A, Hetzer R, Gummert J, EUROMACS members . The European Registry for Patients with Mechanical Circulatory Support (EUROMACS) of the European Association for Cardio‐Thoracic Surgery (EACTS): second report. Eur J Cardiothorac Surg 2018; 53: 309–316. PubMed

Goldstein DJ, Maybaum S, MacGillivray TE, Moore SA, Bogaev R, Farrar DJ, Frazier OH, HeartMate II Clinical Investigators . Young patients with nonischemic cardiomyopathy have higher likelihood of left ventricular recovery during left ventricular assist device support. J Card Fail 2012; 18: 392–395. PubMed

Dandel M, Weng Y, Siniawski H, Potapov E, Lehmkuhl HB, Hetzer R. Long‐term results in patients with idiopathic dilated cardiomyopathy after weaning from left ventricular assist devices. Circulation 2005; 112: I37–I45. PubMed

Birks EJ, Tansley PD, Hardy J, George RS, Bowles CT, Burke M, Banner NR, Khaghani A, Yacoub MH. Left ventricular assist device and drug therapy for the reversal of heart failure. New Engl J Med 2006; 355: 1873–1884. PubMed

George RS, Yacoub MH, Bowles CT, Hipkin M, Rogers P, Hallas C, Banner NR, Dreyfus G, Khaghani A, Birks EJ. Quality of life after removal of left ventricular assist device for myocardial recovery. The Journal of Heart and Lung Transplantation 2008; 27: 165–172. PubMed

Frazier OH, Baldwin ACW, Demirozu ZT, Segura AM, Hernandez R, Taegtmeyer H, Mallidi H, Cohn WE. Ventricular reconditioning and pump explantation in patients supported by continuous‐flow left ventricular assist devices. The Journal of Heart and Lung Transplantation: The Official Publication of the International Society for Heart Transplantation 2015; 34: 766–772. PubMed PMC

Knierim J, Heck R, Pieri M, Schoenrath F, Soltani S, Stawowy P, Dreysse S, Stein J, Müller M, Mulzer J, Dandel M, Falk V, Krabatsch T, Potapov E. Outcomes from a recovery protocol for patients with continuous‐flow left ventricular assist devices. J Heart Lung Transplant 2019; 38: 440–448. PubMed

de By TM, Mohacsi P, Gummert J, Bushnaq H, Krabatsch T, Gustafsson F, Leprince P, Martinelli L, Meyns B, Morshuis M, Netuka I. The European Registry for Patients with Mechanical Circulatory Support (EUROMACS): first annual report. Eur J Cardiothorac Surg 2015; 47: 770–777 discussion 76‐7. PubMed

Kormos RL, Cowger J, Pagani FD, Teuteberg JJ, Goldstein DJ, Jacobs JP, Higgins RS, Stevenson LW, Stehlik J, Atluri P, Grady KL, Kirklin JK. The Society of Thoracic Surgeons Intermacs database annual report: evolving indications, outcomes, and scientific partnerships. The Annals of Thoracic Surgery 2019; 107: 341–353. PubMed

Wever‐Pinzon O, Drakos SG, McKellar SH, Horne BD, Caine WT, Kfoury AG, Li DY, Fang JC, Stehlik J, Selzman CH. Cardiac recovery during long‐term left ventricular assist device support. J Am Coll Cardiol 2016; 68: 1540–1553. PubMed

Drakos SG, Mehra MR. Clinical myocardial recovery during long‐term mechanical support in advanced heart failure: insights into moving the field forward. The Journal of Heart and Lung Transplantation 2016; 35: 413–420. PubMed

Birks EJ, George RS, Hedger M, Bahrami T, Wilton P, Bowles CT, Webb C, Bougard R, Amrani M, Yacoub MH, Dreyfus G, Khaghani A. Reversal of severe heart failure with a continuous‐flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation 2011; 123: 381–390. PubMed

Mann DL, Barger PM, Burkhoff D. Myocardial recovery and the failing heart. J Am Coll Cardiol 2012; 60: 2465. PubMed PMC

Maybaum S, Mancini D, Xydas S, Starling RC, Aaronson K, Pagani FD, Miller LW, Margulies K, McRee S, Frazier OH, Torre‐Amione G, LVAD Working Group . Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD Working Group. Circulation 2007; 115: 2497–2505. PubMed

Drakos SG, Wever‐Pinzon O, Selzman CH, Gilbert EM, Alharethi R, Reid BB, Saidi A, Diakos NA, Stoker S, Davis ES, Movsesian M, Li DY, Stehlik J, Kfoury AG, UCAR (Utah Cardiac Recovery Program) Investigators . Magnitude and time course of changes induced by continuous‐flow left ventricular assist device unloading in chronic heart failure: insights into cardiac recovery. J Am Coll Cardiol 2013; 61: 1985–1994. PubMed PMC

Drakos SG, Kfoury AG, Selzman CH, Verma DR, Nanas JN, Li DY, Stehlik J. Left ventricular assist device unloading effects on myocardial structure and function: current status of the field and call for action. Curr Opin Cardiol 2011; 26: 245–255. PubMed PMC

Baba HA, Grabellus F, August C, Plenz G, Takeda A, Tjan TDT, Schmid C, Deng MC. Reversal of metallothionein expression is different throughout the human myocardium after prolonged left‐ventricular mechanical support. The Journal of Heart and Lung Transplantation 2000; 19: 668–674. PubMed

Bruckner BA, Stetson SJ, Perez‐Verdia A, Youker KA, Radovancevic B, Connelly JH, Koerner MM, Entman ME, Frazier OH, Noon GP, Torre‐Amione G. Regression of fibrosis and hypertrophy in failing myocardium following mechanical circulatory support. The Journal of Heart and Lung Transplantation 2001; 20: 457–464. PubMed

Blaxall BC, Tschannen‐Moran BM, Milano CA, Koch WJ. Differential gene expression and genomic patient stratification following left ventricular assist device support. J Am Coll Cardiol 2003; 41: 1096–1106. PubMed

Rodrigue‐Way A, Burkhoff D, Geesaman BJ, Golden S, Xu J, Pollman MJ, Donoghue M, Jeyaseelan R, Houser S, Breitbart RE, Marks A, Acton S. Sarcomeric genes involved in reverse remodeling of the heart during left ventricular assist device support. The Journal of Heart and Lung Transplantation 2005; 24: 73–80. PubMed

Ogletree‐Hughes ML, Stull LB, Sweet WE, Smedira NG, McCarthy PM, Moravec CS. Mechanical unloading restores β‐adrenergic responsiveness and reverses receptor downregulation in the failing human heart. Circulation 2001; 104: 881–886. PubMed

Bruggink AH, van Oosterhout MFM, de Jonge N, Ivangh B, van Kuik J, Voorbij RHAM, Cleutjens JP, Gmelig‐Meyling FH, De Weger RA. Reverse remodeling of the myocardial extracellular matrix after prolonged left ventricular assist device support follows a biphasic pattern. The Journal of Heart and Lung Transplantation 2006; 25: 1091–1098. PubMed

Li YY, Feng Y, McTiernan CF, Pei W, Moravec CS, Wang P, Rosenblum W, Kormos RL, Feldman AM. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation 2001; 104: 1147–1152. PubMed

Thohan V, Stetson SJ, Nagueh SF, Rivas‐Gotz C, Koerner MM, Lafuente JA, Loebe M, Noon GP, Torre‐Amione G. Cellular and hemodynamics responses of failing myocardium to continuous flow mechanical circulatory support using the DeBakey–Noon left ventricular assist device: a comparative analysis with pulsatile‐type devices. The Journal of Heart and Lung Transplantation 2005; 24: 566–575. PubMed

Dipla K, Mattiello Julian A, Jeevanandam V, Houser Steven R, Margulies KB. Myocyte recovery after mechanical circulatory support in humans with end‐stage heart failure. Circulation 1998; 97: 2316–2322. PubMed

Noguchi T, Hünlich M, Camp Phillip C, Begin Kelly J, El‐Zaru M, Patten R, Leavitt BJ, Ittleman FP, Alpert NR, LeWinter MM, VanBuren P. Thin filament‐based modulation of contractile performance in human heart failure. Circulation 2004; 110: 982–987. PubMed

Ambardekar AV, Buttrick PM. Reverse remodeling with left ventricular assist devices: a review of clinical, cellular, and molecular effects. Circ Heart Fail 2011; 4: 224–233. PubMed PMC

Dandel M, Weng Y, Siniawski H, Stepanenko A, Krabatsch T, Potapov E, Lehmkuhl HB, Knosalla C, Hetzer R. Heart failure reversal by ventricular unloading in patients with chronic cardiomyopathy: criteria for weaning from ventricular assist devices. Eur Heart J 2011; 32: 1148–1160. PubMed PMC